IO Biotech, Inc. Announces $75 Million Private Placement Financing
Offering includes participation from both new and existing healthcare-dedicated investorsProceeds extend the company’s cash runway into the fourth quarter of...
Offering includes participation from both new and existing healthcare-dedicated investorsProceeds extend the company’s cash runway into the fourth quarter of...
LAWRENCEVILLE, N.J., Aug. 07, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral...
FREMONT, CA, Aug. 07, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company...
BASKING RIDGE, N.J., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...
PRINCETON, N.J., Aug. 07, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing...
Study is first of its kind to compare diagnostic rates across short- and long-read sequencing platformsMENLO PARK, Calif. and STAMFORD,...
NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...
SAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on...
HOUSTON, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation...
- Completion of Enrollment in Zunsemetinib Phase 2b Trial in Rheumatoid Arthritis As Previously Announced; Data Expected in Q4 2023...
Topline Results Expected Third Quarter 2023 Long COVID Afflicts Approximately 19% of Patients Following COVID-191, and is Expected to be...
KNOXVILLE, TN, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that preclinical data from ongoing research on...
Ikena receives approximately $43 million in net cash at closing New capital will further accelerate and expand development of Ikena’s...
– First patient dosed in phase 1/2 trial of TNG462, a next-generation PRMT5 inhibitor for the treatment of MTAP-deleted tumors...
Vivoryon Therapeutics N.V. Extraordinary General Meeting to Confirm New Executive Director Appointments to the Board, Being Held on September 15, 2023...
Vivoryon Therapeutics N.V. Announces Proposed Appointment of Dr. Frank Weber as Chief Executive Officer Frank Weber, MD, current Chief Medical...
SOUTH SAN FRANCISCO and SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology...
SEATTLE, WA / ACCESSWIRE / August 4, 2023 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical stage...
DUBLIN--(BUSINESS WIRE)--The "United States Women Health Laboratory Testing Market by Hereditary Cancer, Reproductive Health and Infectious Diseases, Prenatal Screening and...
TURKU, Finland and BOSTON, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical...